Moleculin Biotech furnishes May 2026 investor deck
Moleculin Biotech, Inc. furnished a new investor presentation as part of a current report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Moleculin Biotech, Inc. furnished a new investor presentation as part of a current report. The company is using this May 2026 corporate presentation, attached as Exhibit 99.1, for its website and investor communications. The material is provided under a Regulation FD disclosure item and is expressly treated as “furnished,” not “filed,” which means it is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced later.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Terms
Emerging growth company, Regulation FD disclosure, Inline XBRL, Securities Exchange Act of 1934, +1 more
5 terms
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Regulation FD disclosure regulatory
"The information contained in Item 7.01 of this on , including Exhibit 99.1, is being furnished"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Inline XBRL technical
"104 | Cover page Interactive Data File (formatted as Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Securities Exchange Act of 1934 regulatory
"shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended"
Securities Act of 1933 regulatory
"nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Moleculin Biotech (MBRX) disclose in its latest 8-K filing?
Moleculin Biotech furnished a new investor presentation as Exhibit 99.1. The May 2026 corporate deck is being used for the company’s website and investor communications and is provided under a Regulation FD disclosure item, rather than as a formally filed report.
Is Moleculin Biotech’s May 2026 investor presentation considered filed with the SEC?
No, the investor presentation is being furnished, not filed. The company states that the information in Item 7.01, including Exhibit 99.1, will not be deemed filed or incorporated into other Securities Act or Exchange Act reports unless specifically identified that way later.
What is Exhibit 99.1 in Moleculin Biotech’s (MBRX) May 2026 8-K?
Exhibit 99.1 is an investor presentation dated May 2026. Moleculin Biotech indicates it will use this presentation for corporate and website purposes, and it is attached to the current report strictly as furnished information under the Regulation FD disclosure item.
Which item of the 8-K covers Moleculin Biotech’s investor presentation?
The investor presentation is described under Item 7.01, the Regulation FD disclosure section. Moleculin Biotech explains that the attached Exhibit 99.1 is furnished under this item and will not automatically be treated as filed or incorporated into other SEC documents without explicit identification.
What other exhibits were included in Moleculin Biotech’s May 2026 8-K?
The 8-K lists two exhibits: Exhibit 99.1, the investor presentation dated May 2026, and Exhibit 104, the cover page interactive data file formatted as an Inline XBRL document supporting the structured reporting requirements for the current report’s cover information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 26, 2026
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
On May 26, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
|
|
99.1
|
Investor Presentation dated May 2026
|
|
|
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
May 26, 2026
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
Exhibit 99.1
